Work

P275 Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study

Year: 2023

Type: conference-abstract

Source: Neuromuscular Disorders

DOI: 10.1016/j.nmd.2023.07.442

Authors: J. Vissing, A. Drużdż, J. Grosskreutz, A. Habib, R. Mantegazza, K. Utsugisawa, T. Vu, F. Grimson, R Beau Lejdstrom, I. Pulido-Valdeolivas, T. Tarancón, V. Bril

Institutions: University of Copenhagen, Rigshospitalet, University of Lübeck, University of California, Irvine, Fondazione IRCCS Istituto Neurologico Carlo Besta, General Hanamaki Hospital, University of South Florida, UCB Pharma (United Kingdom), UCB Pharma (Spain), University Health Network

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387301977

Cites:

Cited by: 1

Related to: 10